Compare MPV & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | CRBP |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 184.4M |
| IPO Year | N/A | 2014 |
| Metric | MPV | CRBP |
|---|---|---|
| Price | $15.85 | $8.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 11.5K | ★ 447.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $15.65 | $7.12 |
| 52 Week High | $21.00 | $20.56 |
| Indicator | MPV | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 50.63 |
| Support Level | $15.65 | $7.42 |
| Resistance Level | $17.57 | $9.73 |
| Average True Range (ATR) | 0.36 | 0.48 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 12.70 | 35.87 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.